Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0120 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 0.644 |
Open | 0.6429 |
1-Year Change | -57.7% |
Day's Range | 0.6299 - 0.695 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 2, 2025 | 0.6829 | 0.0360 | 5.57% | 0.6469 | 0.7069 | 0.6269 |
Apr 1, 2025 | 0.6440 | -0.0429 | -6.25% | 0.6869 | 0.7136 | 0.6318 |
Mar 31, 2025 | 0.6984 | -0.0440 | -5.93% | 0.7424 | 0.7605 | 0.6769 |
Mar 28, 2025 | 0.7901 | 0.0882 | 12.57% | 0.7019 | 0.7960 | 0.6970 |
Mar 27, 2025 | 0.7170 | -0.0194 | -2.63% | 0.7364 | 0.7364 | 0.6870 |
Mar 26, 2025 | 0.7332 | 0.0063 | 0.87% | 0.7269 | 0.7347 | 0.6998 |
Mar 25, 2025 | 0.7080 | 0.0431 | 6.48% | 0.6649 | 0.7103 | 0.6285 |
Mar 24, 2025 | 0.6317 | 0.0243 | 4.00% | 0.6074 | 0.6386 | 0.6069 |
Mar 21, 2025 | 0.5911 | 0.0242 | 4.27% | 0.5669 | 0.6016 | 0.5539 |
Mar 20, 2025 | 0.5668 | 0.0399 | 7.57% | 0.5269 | 0.5819 | 0.5269 |
Mar 19, 2025 | 0.5460 | 0.0341 | 6.66% | 0.5119 | 0.5466 | 0.5079 |
Mar 18, 2025 | 0.5130 | -0.0439 | -7.88% | 0.5569 | 0.5569 | 0.5118 |
Mar 17, 2025 | 0.5683 | 0.0203 | 3.70% | 0.5480 | 0.5802 | 0.5389 |
Mar 14, 2025 | 0.5347 | -0.0128 | -2.34% | 0.5475 | 0.5599 | 0.5319 |
Mar 13, 2025 | 0.5430 | -0.0279 | -4.89% | 0.5709 | 0.5709 | 0.5385 |
Mar 12, 2025 | 0.5730 | 0.0120 | 2.14% | 0.5610 | 0.5799 | 0.5518 |
Mar 11, 2025 | 0.5341 | -0.0228 | -4.09% | 0.5569 | 0.5610 | 0.5087 |
Mar 10, 2025 | 0.5527 | -0.0422 | -7.09% | 0.5949 | 0.5971 | 0.5469 |
Mar 7, 2025 | 0.6035 | -0.0187 | -3.01% | 0.6222 | 0.6326 | 0.5997 |
Mar 6, 2025 | 0.6244 | 0.0474 | 8.21% | 0.5770 | 0.6835 | 0.5718 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News

Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com